GKOS
Glaukos Corporation
GKOS lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GKOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Healthy | |
| Weak |
GKOS's revenue and cash flow are currently healthy, but its profitability and balance sheet are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GKOS PE Valuation
GKOS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 170x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GKOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
GKOS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GKOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.44 | — |
| Q3 2026 | -$2.96 | -$1.46 |
| Q2 2026 | -$3.27 | -$1.66 |
| Q1 2026 | -$3.30 | -$1.03 |
| Q4 2025 | -$3.28 | -$0.51 |
| Q3 2025 | -$1.50 | +$1.46 |
| Q2 2025 | -$1.61 | +$1.59 |
| Q1 2025 | -$2.27 | +$0.61 |
| Q4 2024 | -$2.77 | +$0.01 |
GKOS lost $2.96 per share over the past year, a bigger loss than the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GKOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $211M | +58% |
| Q2 2026 | $185.6M | +50% |
| Q1 2026 | $150.6M | +41% |
| Q4 2025 | $143.1M | +36% |
| Q3 2025 | $133.5M | +38% |
| Q2 2025 | $124.1M | +30% |
| Q1 2025 | $106.7M | +25% |
| Q4 2024 | $105.5M | +28% |
GKOS's revenue has grown year over year for 15 quarters in a row: $211M last quarter, up 58% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.4% | +13 points |
| Q2 2026 | -9.3% | +9 points |
| Q1 2026 | -13% | +6.2 points |
| Q4 2025 | -98% | -71 points |
| Q3 2025 | -12% | +13 points |
| Q2 2025 | -18% | +13 points |
| Q1 2025 | -19% | +26 points |
| Q4 2024 | -27% | +20 points |
GKOS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GKOS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GKOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $36.5M | +$48.2M |
| Q2 2026 | $12.1M | +108% |
| Q1 2026 | -$16.5M | +$4M |
| Q4 2025 | $3.9M | +$5.2M |
| Q3 2025 | -$11.7M | -$689K |
| Q2 2025 | $5.8M | +$26.3M |
| Q1 2025 | -$20.5M | +$14.4M |
| Q4 2024 | -$1.2M | +$13.7M |
GKOS's free cash flow has turned positive after six years mostly in the red: $36M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
GKOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +2.4M shares |
| 1 year | +6.6% | +3.8M shares |
| 3 years | +26% | +12.5M shares |
| 5 years | +24% | +11.9M shares |
| Available history | +49% | +20.1M shares |
GKOS has 61M diluted shares, up 6.6% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GKOS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GKOS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | 9.4x | High |
GKOS's net debt is about 9.3 years of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GKOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.8 | Overbought |
| Stochastic | 84.2 | Overbought |
GKOS's weekly RSI is 75 (overbought) and its Stochastic is 84 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GKOS PE vs Healthcare Sector
GKOS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GKOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $192.0 | 28% above |
| 20 week MA | $177.6 | 39% above |
| 50 week MA | $142.0 | 73% above |
| 100 week MA | $123.5 | 99% above |
| 200 week MA | $106.0 | 132% above |
GKOS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GKOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.0 | $74.0 | +35% |
| 2021 | $74.0 | $46.8 | -37% |
| 2022 | $46.8 | $42.6 | -8.9% |
| 2023 | $42.6 | $79.5 | +86% |
| 2024 | $79.5 | $151.2 | +90% |
| 2025 | $151.2 | $116.2 | -23% |
| 2026 YTD | $116.2 | $246.0 | +112% |
GKOS has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.